Navigation Links
Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Date:12/18/2007

and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

ALTROPANE is a registered trademark of Alseres Pharmaceuticals, Inc.

Safe Harbor:

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's clinical development and trials for ALTROPANE, the prospects of FDA approval of ALTROPANE and the commercialization, including partnering opportunities, of ALTROPANE. Forward- looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alse
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014 Imago ... today announced a $26.5 million Series A financing ... firm founded by a team of accomplished investment ... investors participating in the round include Frazier Healthcare, ... Representatives from Clarus Ventures and Frazier Healthcare will ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
(Date:10/31/2014)... Calif. , Oct. 31, 2014 ThynkWare ... sclerosis (ALS) patients initiate text and email messages using ... a patent-pending technology invented by ThynkWare,s founder, Duane ... on a smartphone device. This technology allows users to ... only the power of thought. ThynkWare provides ...
Breaking Medicine Technology:Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ... that Acetadote® ( acetylcysteine ) Injection, an injectable product ... available in the Australian market. Phebra Pty Ltd., an ... U.S.-based Cumberland Pharmaceuticals to market and distribute the product ...
... Biotechnology Corporation (Nasdaq: GNBT ) ( www.generex.com ) ... reverse stock split proposal put forward at the Annual Meeting ... DO NOT COUNT as votes cast in respect of ... Special Meeting of stockholders scheduled for 10 a.m. EDT on ...
Cached Medicine Technology:Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 5Generex Provides Clarification for Special Meeting Voting 2Generex Provides Clarification for Special Meeting Voting 3
(Date:10/31/2014)... Rice University researchers have mapped how information flows through ... metastatic. The research reveals a common pattern in the ... form new tumors. Researchers say the commonality may open ... genetic switches that cancer must flip to form both ... of the main players in cancer metastasis. , "Cells ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org reveals ... father suffered from Alzheimer's disease. , In fact, Alexander ... father's disease. His father pointed a gun and shot him ... the author of this method understood that he needed to ... Healer program is based on years of research. The author ...
(Date:10/31/2014)... Oaks, CA (PRWEB) October 31, 2014 ... tummy also has amazing health effects for practitioners. ... created by a Doctor of Science and Movement ... through his dedication to pelvic floor reeducation that ... of urinary incontinence, Diastasis Recti, Prolepses, etc. , ...
(Date:10/31/2014)... 2014 Activz Whole-Food Nutrition ... line offering natural silver healing support† in liquid ... century, silver has been used to support natural healing, ... is the most advanced version available. This latest formula, ... structure that supports the existing healing mechanisms in the ...
(Date:10/31/2014)... apnea may make it hard for you to remember simple ... your house keys, a small study suggests. Tests on ... -- called spatial memory -- was impaired when sleep apnea ... of sleep weren,t affected. REM sleep is the deepest level ... for the first time that sleep apnea, an increasingly common ...
Breaking Medicine News(10 mins):Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Sleep Apnea May Steal Some of Your Memory: Study 2
... Foundation drives initiative for SCID screening, MILWAUKEE, Jan. ... in the nation to screen all newborns for Severe ... SCID is a,genetic disorder that is fatal without early ... life-saving treatment., The Wisconsin Department of Health and ...
... of Cholestech Brings Strong Financial Expertise ... HAYWARD, Calif., Jan. 3 Thermage, Inc.,(Nasdaq: THRM ... aesthetic,industry, today announced the appointment of John F. (Jack) ... CFO of Cholestech,Corporation, succeeds Laureen DeBuono, who resigned from ...
... depression, even though it doesn,t impact on hot flashes, ... is not a cure for hot flashes, but it does ... Pennsylvania study has found. , The researchers had hoped to ... hormone replacement therapy for women suffering from hot flashes, said ...
... Hispanic ethnic groups and others with a family history of ... glaucoma are particularly vulnerable, SAN ... no early symptoms and do not notice as their peripheral,vision diminishes ... million Americans with the disease are unaware of their condition.,January is ...
... Snack Leader Corazonas Foods Debuts Five Great-Tasting Potato, ... ... Less Fat Than Regular Potato Chips, LOS ANGELES, ... snack foods, transforms the all-American,classic potato chip into a ...
... YORK, Jan. 3 WebMD Health Corp. (Nasdaq:,WBMD) and HLTH Corporation ... to participate at two upcoming investor conferences:, -- The ... 7:00pm Eastern Time (ET) -- The 18th ... Conference on January 9, 2008 at 1:05pm Eastern Time ...
Cached Medicine News:Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 2Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 4Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 5Health News:Thermage, Inc. Appoints John F. Glenn as Chief Financial Officer 2Health News:Thermage, Inc. Appoints John F. Glenn as Chief Financial Officer 3Health News:Exercise Eases Some Menopause Symptoms 2Health News:Exercise Eases Some Menopause Symptoms 3Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:Corazonas Launches First and Only Cholesterol-Reducing Potato Chips 2Health News:WebMD to Present at Upcoming Investor Conferences 2
... of the easiest tests to run on the ... minutes with no hands-on time. Critical care instructions ... child leaving the pediatrician's office and valuable information ... help control the spread of RSV infections. Now ...
... an ultra-high speed, high resolution optical coherence ... imaging and analysis. It is ... Coherence technology just emerging from clinical research ... The ultra-high speed and high resolution features ...
... hCG Combo with Reference Line ... of human chorionic gonadotropin (hCG) ... This test kit is used ... and is intended for professional ...
... Experience the finest surgical-quality loupes ... set the standard for innovative optical ... customer support. Delivering optimum performance with ... clear choice for medical professionals worldwide. ...
Medicine Products: